Abstract Number: 0393 • ACR Convergence 2023
Pulmonary Involvement in Patients with Seropositive and ACPA Positive Rheumatoid Arthritis (RA-ILD) – Novel Screening Protocol for Early Detection of Pulmonary Involvement
Background/Purpose: Seropositive and ACPA positive Rheumatoid Arthritis (RA) is associated with significant cardiovascular and pulmonary comorbidity. However, screening for early detection of pulmonary involvement especially…Abstract Number: 0402 • ACR Convergence 2023
Automated Detection and Quantification of Hand Joint Swelling in Rheumatoid Arthritis: Computer Vision, Deep Neural Network Models, and a Potential Biomarker for Disease Activity Monitoring
Background/Purpose: We have previously shown that automated detection and processing of dorsal finger fold patterns from hand photographs can be used as a digital biomarker…Abstract Number: 0405 • ACR Convergence 2023
Clinical Features of Anti-Th/To Antibodies-positive Systemic Sclerosis Patients: A Single-center Retrospective Study
Background/Purpose: Anti-Th/To antibodies (Abs) have been reported in patients with systemic sclerosis (SSc). The presence of anti-Th/To Abs is detected in 2-5% of SSc cases…Abstract Number: 0409 • ACR Convergence 2023
Prevalence of Pulmonary Manifestations in Patients with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, and Peripheral Spondyloarthritis
Background/Purpose: Pulmonary impairment is a common, yet poorly understood, extraarticular manifestation in rheumatic diseases, which is often inadequately screened and managed. This can result in…Abstract Number: 0353 • ACR Convergence 2023
Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis Using Machine Learning Methods
Background/Purpose: Administrative claims databases represent important settings for studying large populations with juvenile idiopathic arthritis (JIA), but prior efforts to validate diagnostic algorithms for JIA…Abstract Number: 0359 • ACR Convergence 2023
Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment
Background/Purpose: Adalimumab therapeutic drug monitoring (TDM) using established trough concentrations is not standard practice in JIA patients, unlike IBD. No specific guidelines outline a therapeutic…Abstract Number: 0298 • ACR Convergence 2023
Accuracy of the 2017 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) Classification Criteria and Myositis-Specific Autoantibodies-Based Classification Criteria for Classifying Patients with Idiopathic Inflammatory Myopathy
Background/Purpose: Limitations of the 2017 EULAR/ACR classification criteria have been suggested for classifying patients with idiopathic inflammatory myopathies (IIMs) and myositis-specific antibodies (MSAs). On this…Abstract Number: 0355 • ACR Convergence 2023
Long Term Safety of Drugs in Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Evidence on treatment safety in systemic juvenile idiopathic arthritis (sJIA) is limited. Our objective was to evaluate the safety profile of drugs in the…Abstract Number: 0366 • ACR Convergence 2023
Active Joint Acoustic Emissions on the Achilles Tendon: A Digital Biomarker of Enthesitis Related Arthritis
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a chronic condition in children that causes joint inflammation. Enthesitis-related arthritis (ERA), a subtype of JIA, affects 10-20% of…Abstract Number: 0291 • ACR Convergence 2023
Myopathy Related to Small-to-medium-sized Vessel Vasculitis: Immunopathological Characteristics
Background/Purpose: Muscular involvement develops as the initial manifestation of small-sized vessel vasculitis (SV) and medium-sized vessel vasculitis (MV).The musculoskeletal lesion has been found as a…Abstract Number: 0376 • ACR Convergence 2023
Switching Patterns of Biological and Targeted Synthetic Therapies in Juvenile Idiopathic Arthritis
Background/Purpose: New therapies have improved the therapeutic management of juvenile idiopathic arthritis (JIA), allowing disease control in cases that are refractory or intolerant to methotrexate.…Abstract Number: 0379 • ACR Convergence 2023
Clinical Evolution of Patients Diagnosed of Juvenile Idiopathic Arthritis After the Transitional Care Consultation
Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses a group of chronic arthritis that begin in childhood. According to the International League of Associations for Rheumatology (ILAR)…Abstract Number: 0384 • ACR Convergence 2023
Targeting NET Formation in Early RA Patients; A Spin-off Study from the NORD-STAR
Background/Purpose: The formation of neutrophil extracellular traps (NETs) with extrusion of nuclear, granular and cytosolic components from a dying neutrophil, has been described extensively in…Abstract Number: 0386 • ACR Convergence 2023
Functional Disability and Disease Activity Are Affected by Social Determinants of Health in Patients with Rheumatoid Arthritis
Background/Purpose: The relationship between social determinants of health (SDH) (e.g. income, education, and employment status) and disease outcomes in the RA population is not well…Abstract Number: 0315 • ACR Convergence 2023
Identification of Calcium Crystals in End-Stage Osteoarthritis with Raman Spectroscopy
Background/Purpose: Calcium containing crystals in osteoarthritis (OA) are of interest as they potentially stimulate the NRLP-3 inflammasome and may become treatable with novel therapeutics. Previous…
- « Previous Page
- 1
- …
- 190
- 191
- 192
- 193
- 194
- …
- 2425
- Next Page »